[1]张 颖.结直肠癌患者血清SDC4，CXCL1水平检测在临床诊断及淋巴结转移评估中的应用价值[J].现代检验医学杂志,2025,40(01):116-121.[doi:10.3969/j.issn.1671-7414.2025.01.022]
　ZHANG Ying.Application Value of Serum SDC4, CXCL1 Level Detection in Clinical Diagnosis and Lymph Node Metastasis Assessment in Colorectal Cancer Patients[J].Journal of Modern Laboratory Medicine,2025,40(01):116-121.[doi:10.3969/j.issn.1671-7414.2025.01.022]
点击复制

结直肠癌患者血清SDC4，CXCL1水平检测在临床诊断及淋巴结转移评估中的应用价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年01期
页码:
116-121
栏目:
论著
出版日期:
2025-01-15

文章信息/Info

Title:
Application Value of Serum SDC4, CXCL1 Level Detection in Clinical Diagnosis and Lymph Node Metastasis Assessment in Colorectal Cancer Patients
文章编号:
1671-7414（2025）01-116-06
作者:
张 颖
（绵阳市肛肠病医院，四川绵阳 621000）
Author(s):
ZHANG Ying
(Mianyang Anorectal Disease Hospital，Sichuan Mianyang 621000，China)
关键词:
结直肠癌; 多配体蛋白聚糖4; CXC 趋化因子配体1; 淋巴结转移
分类号:
R735.3；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.01.022
文献标志码:
A
摘要:
目的 探讨血清多配体蛋白聚糖4（SDC4），CXC 趋化因子配体1(CXCL1) 在结直肠癌（CRC）诊断及淋巴结转移中的评估价值。方法 收集2021 年1 月～ 2023 年7 月绵阳市肛肠病医院收治的136 例CRC 患者（CRC 组），按照病理学检查是否发生淋巴结转移情况，进一步分为有淋巴结转移组（n=45）和无淋巴结转移组（n=91）。另选取同期136例结直肠息肉患者作为对照组。采用ELISA 法检测患者血清SDC4 和CXCL1 表达水平。多因素Logistic 回归分析影响CRC 发生及CRC 患者淋巴结转移的因素；ROC 曲线分析血清SDC4，CXCL14 对CRC 的诊断及对淋巴结转移的评估价值。结果 CRC 组血清SDC4（9.13±2.54ng/L ）和CXCL1（96.16±20.16pg/ml）水平明显高于对照组（7.24±2.11ng/L，78.59±16.27pg/ml），差异具有统计学意义（t=6.662，7.909，均P ＜ 0.05）。CRC 患者Ⅲ + Ⅳ期血清SDC4（9.85±2.14ng/L vs）和CXCL1（98.71±9.51pg/ml）表达水平显著高于Ⅰ + Ⅱ期（8.61±2.12ng/L，94.32±8.56pg/ml），低分化组血清SDC4（9.72±2.12ng/L）和CXCL1（103.15±17.56pg/ml）表达水平显著高于高中分化组（8.59±1.78ng/L，89.76±16.23pg/ml），差异具有统计学意义（t=3.352，2.816；3.376，4.621，均P ＜ 0.05）。有淋巴结转移组血清SDC4（9.21±0.09ng/L）和CXCL1（99.98±4.52pg/ml）水平明显高于无淋巴结转移组（9.09±0.08ng/L，94.27±4.06pg/ml），差异具有统计学意义（t=7.894，7.431，均P ＜ 0.05）。多因素Logistic 回归分析显示：血清SDC4，CXCL1 是影响CRC 发生及CRC 患者淋巴结转移的危险因素（均P ＜ 0.05）。ROC 曲线显示，血清SDC4，CXCL1 及二者联合诊断CRC 的AUC（95%CI）为0.746(0.688 ～ 0.803)，0.755(0.698 ～ 0.812) 和0.835(0.787 ～ 0.883)，二者联合优于SDC4，CXCL1 各自单独诊断，差异具有统计学意义（Z=2.364，2.125，均P ＜ 0.05）。血清SDC4，CXCL1 及二者联合评估淋巴结转移的AUC（95%CI）分别为0.819(0.738 ～ 0.899)，0.794(0.709 ～ 0.880)，0.922(0.875 ～ 0.968)，二者联合优于SDC4，CXCL1 各自单独评估，差异具有统计学意义（Z=2.168，2.599，均P ＜ 0.05）。结论 CRC 患者血清SDC4 和CXCL1 水平升高与淋巴结转移有关，可作为诊断CRC 及评估淋巴结转移的重要生物学指标。
Abstract:
Objective To investigate the value of serum syndecan-4 (SDC4) and CXC chemokine ligand 1 (CXCL1) in the diagnosis of colorectal cancer (CRC) and lymph node metastasis assessment value. Methods 136 cases of CRC patients (CRC group) admitted to Mianyang Anorectal Disease Hospital from January 2021 to July 2023 were collected and further divided into with lymph nodemetastasis（n=45）and without lymph node metastasis according（n=91）to whether lymph node metastasis had occurred in the pathological examination. Another 136 patients with colorectal polyps were selected as the control group in the same period. ELISA detected the serum SDC4 and CXCL1 expression levels of the patients．Multifactorial Logistic regression was used to analyze the factors affecting the occurrence of CRC and lymph node metastasis in CRC patients, and the ROC curve was used to analyze the value of serum SDC4 and CXCL14 in the diagnosis of CRC and the assessment of lymph node metastasis. Results Serum SDC4 (9.13±2.54ng/L ) and CXCL1 (96.16±20.16pg/ml) levels in the CRC group were significantly higher than those in the control group（7.24±2.11ng/L，78.59±16.27pg/ml）, and the differences were statistically significant (t=6.662，7.909，all P< 0.05)．Serum SDC4 (9.85±2.14ng/L) and CXCL1 (98.71±9.51pg/ml) expression levels were significantly higher in CRC patients with stage III+IV than in stage I+II（8.61±2.12ng/L，94.32±8.56pg/ml）, and lowdifferentiated serum SDC4 (9.72 ± 2.12 ng/L) and CXCL1 (103.15 ± 17.56 pg/ml) expression levels were significantly higher than that of high and middle differentiation（8.59±1.78ng/L，89.76±16.23pg/ml）, and the differences were statistically significant (t=3.352，2.816；3.376，4.621，all P<0.05)． Serum SDC4 (9.21±0.09ng/L) and CXCL1 (99.98±4.52pg/ml) levels were significantly higher than those of the group without lymph node metastasis（9.09±0.08ng/L，94.27±4.06pg/ml）, and the differences were all statistically significant (t=7.894，7.431，all P < 0.05). Multifactorial Logistic regression analysis showed that serum SDC4 and CXCL1 were risk factors for CRC and lymph node metastasis in CRC patients (P < 0.05).ROC curves showed that the AUC(95%CI) of serum SDC4, and CXCL1 the combination of the two in the diagnosis of CRC were 0.746(0.688~0.803), 0.755(0.698~0.812), 0.835(0.787~0.883), and the combination of the two was superior to SDC4. The combination was superior to SDC4, and CXCL1 each diagnosed alone, and the differences were statistically significant (Z=2.364, 2.125, all P<0.05). The AUC(95%CI) of serum SDC4, CXCL1 and the combination of the two in assessing lymph node metastasis were 0.819(0.738~0.899), 0.794(0.709~0.880) and 0.922(0.875~0.968), respectively, and the combination of the two was superior to SDC4, CXCL1 each alone, and the differences were statistically significant (Z=2.168, 2.599, all P<0.05). Conclusion Elevated serum SDC4 and CXCL1 levels in CRC patients are associated with lymph node metastasis and can be used as an important biological indicator for the diagnosis of CRC and assessment of lymph node metastasis.

参考文献/References:

[1] PATEL S G, KARLITZ J J, YEN T, et al. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection[J]. the Lancet Gastroenterology Hepatology, 2022, 7(3): 262-274.
[2] 靳杨，姜利琼，房烨，等．结直肠癌患者血清外泌体与组织中KRAS,BRAF,NRAS 和PIK3CA 基因突变检测及临床意义的比较[J]. 现代检验医学杂志,2023,38(1):22-26．JIN Yang, JIANG Liqiong, FANG Ye, et al. Comparison of KRAS,BRAF,NRAS and PIK3CA gene mutations in serum exosomes and tissues of patients with colorectal cancer and their clinical significance [J]. Journal of Modern Laboratory Medicine , 2023, 38(1): 22-26.
[3] 姜秋利，鲁华东，郑景妹，等．结直肠癌组织中RREB1 和ANKRD1 的表达与临床病理特征和预后的相关性研究[J]. 现代检验医学杂志,2023,38(1):16-21． JIANG Qiuli, LU Huadong, ZHENG Jingmei, et al. Correlation between the expression of RREB1 and ANKRD1 and clinicopathological features and prognosis in colorectal cancer [J]. Journal of Modern Laboratory Medicine, 2023, 38(1): 16-21.
[4] 张玲，兰家秀，王智敏，等．结直肠癌组织多配体蛋白聚糖-4(SDC4) 蛋白表达与临床病理参数及短期预后的关联[J]. 中国实验诊断学,2022,26(11):1669-1672． ZHANG Ling, LAN Jiaxiu, WANG Zhimin, et al. Correlation of syndecan-4(SDC4)protein expression with clinicopathological parameters and short-term prognosis in colorectal cancer tissues [J]. Chinese Journal of Laboratory Diagnosis, 2022, 26(11): 1669-1672.
[5] KORBECKI J, BARCZAK K, GUTOWSKA I, et al. CXCL1: gene, promoter, regulation of expression, mRNA stability, regulation of activity in the intercellular space[J]. International Journal of Molecular Sciences, 2022, 23(2): 792.
[6] 中华人民共和国卫生和计划生育委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2017 年版)[J]. 中华外科杂志，2018，56（4）：241-258． Hospital Authority of National Health and Family Planning Commission of the People’s Republic of China，Chinese Society of Oncology．Chinese protocol of diagnosis and treatment of colorectal cancer(2017 Edition) [J]. Chinese Journal of Surgery, 2018, 56(4): 241-258.
[7] 张国庆，俞咏梅，汤永祥，等．双源CT 对结直肠癌淋巴结转移的鉴别价值[J]. 沈阳医学院学报，2023,25(2):136-140, 144. ZHANG Guoqing, YU Yongmei, TANG Yongxiang, et al. Differential value of dual-source CT in lymph node metastasis of colorectal cancer [J]. Journal of Shenyang Medical College, 2023, 25(2): 136-140, 144.
[8] ZWAGER L W, BASTIAANSEN B A J, MONTAZERI N S M, et al. Deep submucosal invasion is not an independent risk factor for lymph node metastasis in T1 colorectal cancer: a meta-analysis [J]. Gastroenterology, 2022, 163(1): 174-189.
[9] ONYEISI J O S, LOPES C C, G?TTE M. Syndecan-4 as a pathogenesis factor and therapeutic target in cancer[J]. Biomolecules, 2021, 11(4): 503.
[10] PESSOLANO E, BELVEDERE R, NOVIZIO N, et al. Mesoglycan connects Syndecan-4 and VEGFR2 through annexin A1 and Formyl peptide receptors to promote angiogenesis in vitro [J]. FEBS Journal, 2021, 288(22): 6428-6446.
[11] KELLER-PINTER A, GYULAI-NAGY S, BECSKY D, et al. Syndecan-4 in tumor cell motility[J]. Cancers (Basel), 2021, 13(13): 3322.
[12] PO?AS J,MARQUES C, GOMES C, et al. Syndecan-4 is a maestro of gastric cancer cell invasion and communication that underscores poor survival [J]. Proceedings of the National Academy of Sciences of the USA, 2023, 120(20): e2214853120.
[13] JECHOREK D, HAEUSLER-PLISKE I, MEYER F, et al. Diagnostic value of syndecan-4 protein expression in colorectal cancer [J]. Pathology - Research and Practice, 2021, 222: 153431.
[14] ONYEISI J O S, GREVE B, ESPINOZA-S?NCHEZ N A, et al. MicroRNA-140-3p modulates invasiveness, motility, and extracellular matrix adhesion of breast cancer cells by targeting syndecan-4 [J]. Journal of Cellular Biochemistry, 2021, 122(10): 1491-1505.
[15] CHEN Huarong，PAN Yasi，ZHOU Qiming，et al. METTL3 inhibits antitumor immunity by targeting m6A-BHLHE41-CXCL1/CXCR2 axis to promote colorectal cancer [J]. Gastroenterology, 2022, 163(4): 891-907.
[16] ZHUO Changhua, RUAN Qiang, ZHAO Xiangqian, et al. CXCL1 promotes colon cancer progression through activation of NF-κB/P300 signaling pathway [J]. Biology Direct, 2022, 17(1): 34.
[17] PARK Y L, KIM H P, OCK C Y, et al. EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer [J]. Oncogene, 2022, 41(14): 2026-2038.
[18] KORBECKI J, BOSIACKI M, BARCZAK K, et al. The clinical significance and role of CXCL1 chemokine in gastrointestinal cancers [J]. Cells, 2023, 12(10): 1406.
[19] CASASANTA M A, YOO C C, UDAYASURYAN B, et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration [J]. Science Signaling, 2020, 13(641): eaba9157.
[20] ?UKASZEWICZ-ZAJ?C M, P?CZEK S, MROCZKO P, et al. The significance of CXCL1 and CXCL8 as well as their specific receptors in colorectal cancer [J]. Cancer Management and Research, 2020, 12: 8435-8443.
[21] ?UKASZEWICZ-ZAJ?C M, ZAJKOWSKA M, P?CZEK S, et al. The significance of CXCL1 and CXCR1 as potential biomarkers of colorectal cancer [J]. Biomedicines, 2023, 11(7): 1933.

相似文献/References:

[1]陈建国.结直肠癌患者FOLFOX化疗与GSTP1,XRCC1基因多态性的研究[J].现代检验医学杂志,2016,31(05):66.[doi:10.3969/j.issn.1671-7414.2016.05.017]
　CHEN Jian-guo.Relationship between FOLFOX Chemotherapy of Colorectal Cancer Patients and GSTP1,XRCC1 Gene Polymorphism[J].Journal of Modern Laboratory Medicine,2016,31(01):66.[doi:10.3969/j.issn.1671-7414.2016.05.017]
[2]周秋媛,王红莉,李虹,等.NRP-1和NRP-2在结直肠癌组织中的表达水平及临床意义[J].现代检验医学杂志,2016,31(06):85.[doi:10.3969/j.issn.1671-7414.2016.06.024]
　ZHOU Qiu-yuan,WANG Hong-li,LI Hong,et al.Serum NRP-1 and NRP-2 Expression in Colorectal Cancer Patients and Its Relationship with Clinical Pathology[J].Journal of Modern Laboratory Medicine,2016,31(01):85.[doi:10.3969/j.issn.1671-7414.2016.06.024]
[3]史 敏,郭晓波,李思远,等.结直肠癌患者组织中K-ras和BRAF基因突变与不同病理特征的相关性分析[J].现代检验医学杂志,2018,33(03):27.[doi:10.3969/j.issn.1671-7414.2018.03.009]
　SHI Min,GUO Xiao-bo,LI Si-yuan,et al.Correlation of K-ras and BRAF Mutations with Pathological Features in Patients with Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):27.[doi:10.3969/j.issn.1671-7414.2018.03.009]
[4]井丰军,倪勇.结直肠癌患者外周血NLR与RDW的变化及临床意义[J].现代检验医学杂志,2018,33(03):99.[doi:10.3969/j.issn.1671-7414.2018.03.025]
　JING Feng-jun,NI Yong.Change and Significance of Neutrophil/Lymphocyte Ratio and Red Blood Cell Distribution Width of Peripheral Blood in the Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):99.[doi:10.3969/j.issn.1671-7414.2018.03.025]
[5]滕祥云,王新梦,刘　维,等.中国汉族结直肠癌患者 UGT1A1*28基因多态性分析[J].现代检验医学杂志,2019,34(06):20.[doi:10.3969 ／ j.issn.1671-7414.2019.06.005]
　TENG Xiang-yun,WANG Xin-meng,LIU Wei,et al.Polymorphism of UGT1A1*28 Gene in Han Patients with Colorectal Cancer in China[J].Journal of Modern Laboratory Medicine,2019,34(01):20.[doi:10.3969 ／ j.issn.1671-7414.2019.06.005]
[6]陈 培,邓钦木,李丹丹.血浆Septin9 甲基化检测在结直肠癌中的诊断价值[J].现代检验医学杂志,2020,35(04):10.[doi:10.3969/j.issn.1671-7414.2020.04.003]
　CHEN Pei,DENG Qin-mu,LI Dan-dan.Diagnostic Value of Plasma Septin9 Methylation in Screening of Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2020,35(01):10.[doi:10.3969/j.issn.1671-7414.2020.04.003]
[7]杨婕琳a,陈文婷b,胡晓利a.结直肠癌组织中硫氧还蛋白-1与硫氧还蛋白互作蛋白的表达及其临床意义[J].现代检验医学杂志,2021,36(06):22.[doi:10.3969/j.issn.1671-7414.2021.06.005]
　YANG Jie-lin,CHEN Wen-ting,HU Xiao-li.Expression and Clinical Significance of Thioredoxin-1 and Thioredoxin Interacting Protein in Colorectal Cancer[J].Journal of Modern Laboratory Medicine,2021,36(01):22.[doi:10.3969/j.issn.1671-7414.2021.06.005]
[8]马胜辉,崔雪琴,李建华,等.结直肠癌组织miR-485-5p，miR-1207-3p和miR-590-3p水平表达与临床病理特征及生存的相关性研究[J].现代检验医学杂志,2022,37(03):16.[doi:10.3969/j.issn.1671-7414.2022.03.004]
　MA Sheng-hui,CUI Xue-qin,LI Jian-hua,et al.Correlation of miR-485-5p, miR-1207-3p, miR-590-3p Level Expression and Clinicopathologic Characteristics and Survival in Colorectal Cancer Tissue[J].Journal of Modern Laboratory Medicine,2022,37(01):16.[doi:10.3969/j.issn.1671-7414.2022.03.004]
[9]胡道军,史文杰,孙 敏.LncRNA NEAT1/miR-23b-3p/KLF3 轴调控结直肠癌细胞的生物学功能研究[J].现代检验医学杂志,2022,37(04):1.[doi:10.3969/j.issn.1671-7414.2022.04.001]
　HU Dao-jun,SHI Wen-jie,SUN Min.LncRNA NEAT1/miR-23b-3p/ KLF3 Axis Regulates the Biological Function of Colorectal Cancer Cells[J].Journal of Modern Laboratory Medicine,2022,37(01):1.[doi:10.3969/j.issn.1671-7414.2022.04.001]
[10]冯 芬.结直肠癌组织中USP11 和PPP1CA 表达水平与临床病理的相关性研究[J].现代检验医学杂志,2022,37(04):43.[doi:10.3969/j.issn.1671-7414.2022.04.009]
　FENG Fen.Correlation between USP11 and PPP1CA Expression Levels and Clinicopathology in Colorectal Cancer Tissues[J].Journal of Modern Laboratory Medicine,2022,37(01):43.[doi:10.3969/j.issn.1671-7414.2022.04.009]

备注/Memo

备注/Memo:
作者简介：张颖（1979-）男，本科，副主任医师，主要从事肛肠病相关研究，E-mail：zzzt789@163.com。
更新日期/Last Update: 2025-01-15